Literature DB >> 1438278

The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis.

E P Rieber1, C Federle, C Reiter, S Krauss, L Gürtler, J Eberle, F Deinhardt, G Riethmüller.   

Abstract

Infectious cellular uptake of human immunodeficiency virus (HIV) is initiated by a complex sequence of interactions between the viral envelope gp120/gp41 complex and the cellular CD4 receptor resulting in the exposure of a hydrophobic region of gp41 that mediates the irreversible fusion of the virus with the cell membrane. Here we show that viral penetration into a susceptible cell can be inhibited by the high-affinity monoclonal CD4 antibody (CD4 mAb) M-T413 even when it is added as late as 30-120 min after the initial contact of virus with the cell membrane. Inhibition of infection was assessed by monitoring cultures for 34 days after exposure to virus using four different methods simultaneously, including detection of viral DNA by PCR. The interval during which HIV remains sensitive to postbinding neutralization by CD4 mAb depends on strain of virus and type of target cell. Preparations of recombinant soluble CD4 (and the immunoadhesin CD4-IgG1) were much less efficient when compared with mAb M-T413, particularly in blocking infection by fresh HIV-1 isolates. Also cellular transmission of HIV, as determined by syncytia formation within 24 hr, was prevented by mAb M-T413 when added within 45 min of contact of infected H9 cells with uninfected C8166 cells. Together with the favorable clinical experience obtained with CD4 mAbs as immunomodulatory drugs, these data suggest that infusion of CD4 mAb M-T413 may be a therapeutic modus for immediate prophylactic intervention after occupational exposure to HIV and for prevention of intrapartum mother-to-infant HIV transmission.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1438278      PMCID: PMC50428          DOI: 10.1073/pnas.89.22.10792

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  HIV interactions with CD4: a continuum of conformations and consequences.

Authors:  L E Eiden; J D Lifson
Journal:  Immunol Today       Date:  1992-06

2.  Infection of monocytes/macrophages by HIV in vitro.

Authors:  H von Briesen; R Andreesen; R Esser; W Brugger; C Meichsner; K Becker; H Rübsamen-Waigmann
Journal:  Res Virol       Date:  1990 Mar-Apr

3.  Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis.

Authors:  J Prinz; O Braun-Falco; M Meurer; P Daddona; C Reiter; P Rieber; G Riethmüller
Journal:  Lancet       Date:  1991-08-03       Impact factor: 79.321

4.  High risk of HIV-1 infection for first-born twins. The International Registry of HIV-exposed Twins.

Authors:  J J Goedert; A M Duliège; C I Amos; S Felton; R J Biggar
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

5.  HIV in pregnant women and their offspring: evidence for late transmission.

Authors:  A Ehrnst; S Lindgren; M Dictor; B Johansson; A Sönnerborg; J Czajkowski; G Sundin; A B Bohlin
Journal:  Lancet       Date:  1991-07-27       Impact factor: 79.321

6.  Penetration of CD4 T cells by HIV-1. The CD4 receptor does not internalize with HIV, and CD4-related signal transduction events are not required for entry.

Authors:  G M Orloff; S L Orloff; M S Kennedy; P J Maddon; J S McDougal
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

7.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.

Authors:  A Ashkenazi; D H Smith; S A Marsters; L Riddle; T J Gregory; D D Ho; D J Capon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.

Authors:  E S Daar; T Moudgil; R D Meyer; D D Ho
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

View more
  13 in total

1.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Exceptional fusogenicity of Chinese hamster ovary cells with murine retroviruses suggests roles for cellular factor(s) and receptor clusters in the membrane fusion process.

Authors:  D C Siess; S L Kozak; D Kabat
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

3.  Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment.

Authors:  J Bestman-Smith; J Piret; A Désormeaux; M J Tremblay; R F Omar; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

4.  Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor.

Authors:  E J Platt; N Madani; S L Kozak; D Kabat
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

5.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon.

Authors:  L G Gürtler; P H Hauser; J Eberle; A von Brunn; S Knapp; L Zekeng; J M Tsague; L Kaptue
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.

Authors:  N Yahi; J Fantini; S Baghdiguian; K Mabrouk; C Tamalet; H Rochat; J Van Rietschoten; J M Sabatier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

8.  Neutralization of respiratory syncytial virus after cell attachment.

Authors:  C Osiowy; R Anderson
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

9.  Involvement of human leukocyte antigen class I molecules in human immunodeficiency virus infection of CD4-positive cells.

Authors:  M Benkirane; D Blanc-Zouaoui; M Hirn; C Devaux
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120.

Authors:  Y K Fu; T K Hart; Z L Jonak; P J Bugelski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.